Shorts

1:31
The UroOnc Minute: Rethinking battle metaphors in cancer care
4 hours ago
by
Adam B. Weiner, MD(+1 more)

0:35
How diabetes can change bladder sensation and emptying
3 days ago
by
Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, MSCP, HAES

0:50
Expanding aquablation access in the ASC setting
4 days ago
by
Adam Mellis, MD, FACS

1:14
Why urine cfRNA may be more reliable than urine tumor DNA
5 days ago
by
Maximilian Diehn, MD, PhD

0:23
BCG-naïve NMIBC: Priorities for improving outcomes
6 days ago
by
Vignesh T. Packiam, MD

0:30
Why BPH treatment after pelvic radiation is challenging
7 days ago
by
Reem Khondakar, MD

0:24
Why Dr. Spier wanted to lead LUGPA
9 days ago
by
Jeffrey M. Spier, MD

0:19
Phone agents and report automation: Starting AI in practice
10 days ago
by
Jared Olafsson, MS

0:20
Genomics over volume in intensifying prostate cancer therapy
10 days ago
by
Benjamin Garmezy, MD

0:44
From liver to kidney: The next questions for histotripsy
11 days ago
by
William C. Huang, MD

0:39
Making the most of networking at the LUGPA Annual Meeting
13 days ago
by
Benjamin H. Lowentritt, MD, FACS

0:20
New guidelines recognize penoscrotal decompression for priapism
14 days ago
by
Juan J. Andino, MD, MBA

0:35
Administrators, coordinators, and lab directors at LUGPA
17 days ago
by
Benjamin H. Lowentritt, MD, FACS

0:30
Expert: Belzutifan plus lenvatinib advances outcomes in advanced ccRCC
18 days ago
by
Daniel Heng, MD, MPH, FRCPC

0:57
What urine cell-free RNA can reveal about bladder cancer
19 days ago
by
Maximilian Diehn, MD, PhD

0:26
When voiding difficulty points to underactive bladder
20 days ago
by
Ariana L. Smith, MD

0:26
Dr. Lowentritt's LUGPA 2027 pick: Friday afternoon breakouts
21 days ago
by
Benjamin H. Lowentritt, MD, FACS

0:30
Correcting misconceptions about hormone therapy for GSM
25 days ago
by
Engy Habashy, MD

1:29
How gravity instillation may improve gem/doce feasibility
a month ago
by
Adam B. Weiner, MD(+1 more)

0:50
Expert: Anktiva approval sets precedent for papillary-only NMIBC
a month ago
by
JJ Zhang, MD

0:22
Why underactive bladder stays under the radar
a month ago
by
Ariana L. Smith, MD

0:42
The hidden long-term cost of OAB step therapy
a month ago
by
Anjali Kapur, MD

0:35
PCARE and PROs: Addressing penile cancer's hidden burden
a month ago
by
Luis G. Medina, MD

0:18
Exploring intranasal PDE5 inhibitor delivery for erectile dysfunction
a month ago
by
Melissa Hadley Barrett

0:40
Challenging misconceptions about proximal shunting
a month ago
by
Juan J. Andino, MD, MBA

1:12
Belzutifan plus lenvatinib offers a new option after IO in ccRCC
a month ago
by
Mina M. Fam, MD

1:01
Decipher score may help guide short-term ADT use
a month ago
by
Angela Jia, MD, PhD

1:05
Cost-effectiveness model favors beta-3 agonists for OAB
a month ago
by
Anjali Kapur, MD

1:21
New treatment options complicate BCG-unresponsive NMIBC care
a month ago
by
Adam B. Weiner, MD(+1 more)

1:29
Why female sexual health is often overlooked in bladder cancer care
a month ago
by
Armine K. Smith, MD
Advertisement
Advertisement
Trending on Urology Times
1
Treatment interruptions in prostate cancer: Balancing PSA kinetics and quality of life
2
Cretostimogene reduces recurrence risk by 68% in phase 3 PIVOT-006 trial in NMIBC
3
FDA approves durvalumab plus enfortumab vedotin for cisplatin-ineligible MIBC
4
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
5
